Anti-Human CD22 Therapeutic Antibody (hLL2-Cys)
The anti-CD22 Antibody-Drug Conjugates comprise a drug moiety, an anti-CD22 antibody and a hydrophilic self-immolative linker. The antibody in this ADC compound specifically target human cluster of differentiation-22, which belongs to the SIGLEC family of lections. Therefore the anti-CD22 ADC compound can be used in the treatment or diagnosis of hematological malignancy.
Supplier | Creative Biolabs |
---|---|
Product # | TAB-0197CL |
Pricing | Inquiry |
Host | Human |
Target | CD22 |